Skip to content
Buy This GLP
← Research
Evidence

Can You Switch From Tirzepatide to Semaglutide?

A published case and a UK service report describe the switch. Neither establishes how much weight people typically lose after changing treatments.

Editorial profile: Wesley JenkinsBuy This GLP Editorial Team4 min read
Weight at each visit in one published caseStarting weight: 115 kgFirst 6 months · Tirzepatide109.5 kgNext 6 months · Semaglutide92 kg20% below the starting weight after 12 months.

A prescriber can consider switching from tirzepatide to semaglutide when semaglutide is appropriate for the condition being treated. The U.S. Wegovy and Zepbound labels advise against combining them with other GLP-1 medicines. Ask your prescriber to plan the change [4] [5].

What direct evidence on the switch shows

The evidence on switching from semaglutide to tirzepatide includes different patients and study designs. In one report on the reverse switch, a 40-year-old man with obesity lost less than 5% of his weight during six months of tirzepatide treatment. His weight went from 115 kg at baseline to 109.5 kg before switching and 92 kg six months after starting semaglutide. The 20% figure measures total loss from his original baseline [1].

A UK service reported at the 2026 UK Congress on Obesity that it switched 3,291 patients from tirzepatide to semaglutide. It reviewed reports of potentially significant side effects over a short period. The abstract did not report weight outcomes after switching or estimate a comparative safety effect [2].

What the head-to-head trial measured

In SURMOUNT-5, adults with obesity and without type 2 diabetes were assigned to tirzepatide or semaglutide. Estimated average weight loss at week 72 was 20.2% with tirzepatide compared with 13.7% with semaglutide. Those figures come from separate randomized groups. The trial did not measure weight after changing from tirzepatide to semaglutide[3].

What to discuss with your prescriber

The monthly GLP-1 cost guide explains how cash prices, coverage and drug formulation affect the bill. Bring information about why you want to switch and how you responded to your current medicine so the prescriber can weigh treatment options.

Frequently asked

Can you switch from tirzepatide to semaglutide?
A prescriber can consider the change if semaglutide is appropriate for you. The Wegovy and Zepbound prescribing information advises against combining these medicines with other GLP-1 therapy.
Can you predict weight loss after switching?
The published case describes one patient's response, and the UK conference report did not give long-term weight outcomes. The randomized head-to-head trial compared separate groups and did not study a switch.

Sources

  1. [1] La Vignera S, Condorelli RA (2026). Tirzepatide non-response with subsequent semaglutide response in class 2 obesity JCEM Case Reports. PMID 42670558
  2. [2] Kenneally S (2026). Dosing protocol for switching patients with overweight/obesity between semaglutide and tirzepatide based on prescribing data International Journal of Obesity, UK Congress on Obesity abstract P20. Source
  3. [3] Aronne LJ, Horn DB, le Roux CW, et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity New England Journal of Medicine. PMID 40353578
  4. [4] Novo Nordisk (2026). Wegovy prescribing information DailyMed, U.S. National Library of Medicine. Source
  5. [5] Eli Lilly and Company (2026). Zepbound prescribing information DailyMed, U.S. National Library of Medicine. Source

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence